By: Christopher Parrella, Esq., CPC, CHC, CPCO
Parrella Health Law, Boston, MA.
A Health Care Provider Defense and Compliance Firm.

Every once in a while, a case comes along that is so factually straightforward and yet so operationally instructive that it should be required reading for providers. This is one of those cases. A Washington physician just pleaded guilty to adulterating and misbranding medical devices and was sentenced to federal prison, fines and restitution after running what, at its core, was a very simple scheme. He is alleged to have purchased recalled CPAP and BiPAP devices, attempted to “fix” them himself, gave them to patients and billed Medicaid as if they were new.

That is the headline. The real lesson is everything underneath it. To understand how this happened, you need to start with the recall. In June 2021, certain Philips Respironics CPAP and BiPAP devices were subject to a Class I recall, meaning there was a reasonable probability of serious harm or death due to foam degradation inside the machines. The devices were not defective in a minor way. They presented inhalation and toxicity risks. That matters, because once a device is subject to that type of recall, the regulatory framework around it becomes very strict.

Instead of removing those devices from circulation, the physician purchased more than 500 of them on the secondary market. He then had staff, including individuals under his direct supervision, physically open the machines and attempt to remove the recalled foam using basic tools like screwdrivers and hooks. This work was not done in a controlled manufacturing environment, not done in compliance with FDA requirements, and not validated in any way.

At that point, the problem is already significant from a regulatory standpoint. Under federal law, once you alter a medical device in a way that affects its safety or performance, you are effectively stepping into the role of a manufacturer. That triggers FDA requirements, including approval or clearance. None of that happened here.

But the case does not stop there. The altered devices were then provided to Medicaid patients through the physician’s clinic and the clinic billed Washington State Medicaid as if the devices were new, safe and in good working order. There are three layers of exposure in this type of conduct and this is where providers should pay attention. What makes this case particularly instructive is how operational it is. This was not a complex billing scheme involving coding nuances or documentation disputes. This was a series of decisions made at the operational level. Acquire equipment, modify it, deploy it, bill for it. Each step, taken in isolation, may have seemed manageable. Together, they created a clear enforcement case.

The other takeaway is how quickly this type of conduct escalates across agencies. This case involved the Department of Justice, the FDA’s Office of Criminal Investigations and HHS-OIG. That kind of coordination is becoming more common. Once conduct touches patient safety, billing, and federal program funds, multiple agencies have jurisdiction and will act.

From a compliance standpoint, the lesson is straightforward. You cannot separate operations from compliance. Decisions about equipment sourcing, refurbishment and deployment are not just operational decisions. They are regulatory decisions. They implicate FDA rules, payer requirements, and fraud and abuse laws all at once. The bottom line is this. If a device is recalled, altered or otherwise outside of its approved condition, you need to stop and assess the regulatory implications before it ever reaches a patient or a claim form. There is no workaround that justifies bypassing that analysis.

If you have any questions or comments about the subject of this blog, please contact Parrella Health Law at 857.328.0382 or Chris directly at cparrella@parrellahealthlaw.com.